Study: AstraZeneca reinforcement dosage effective against Omitron

The three-dosage vaccine of the company “AstraZeneca” is effective against the Omitron version of the coronary, the company said Thursday, citing the data from an Oxford University laboratory study. The study, which has not yet been published in a medical journal, showed that the levels of antibodies against Omitron after the strengthening dose were [...]
The study, which has not yet been published in a medical journal, showed that the level of antibodies against Omitron after the reinforcement dose was higher in the vaccinated persons and in those who have been naturally cured by Coddy-19.
The renowned company said that after three doses of the vaccine, neutralisation levels against Omicron were similar to those against the Delta version after two doses, Reuters writes.
Anglo-Swedian drug producer said scientists at Oxford University, who made the study, were independent of those who worked on developing the vaccine.
Otherwise, Israel is expected to become the first state in the world to offer the fourth dose of vaccine for health workers, persons over 60 and those with weakened immune systems.
Israeli Prime Minister Naphtali Bennett welcomed the recommendation of a group of experts at the Health Ministry for giving four doses for certain groups, saying this is “a wonderful news that will help us to overcome the wave of Omicron, which is spreading around the world”.












